Unicycive Therapeutics (UNCY) Other Non-Current Liabilities (2022 - 2026)

Unicycive Therapeutics (UNCY) has 5 years of Other Non-Current Liabilities data on file, last reported at $21.7 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 104.9% year-over-year to $21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.7 million (up 104.9% YoY) and the FY2025 annual result came in at $16.9 million, down 10.67% from the prior year.
• Other Non-Current Liabilities improved to $21.7 million in Q1 2026, from $16.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $24.9 million in Q1 2024 to a low of $6.4 million in Q3 2024.
• A 5-year average of $13.4 million and a median of $12.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2025 — Other Non-Current Liabilities tumbled 57.55% — and 2026, when it soared 104.9%.
• Tracing UNCY's Other Non-Current Liabilities over 5 years: stood at $10.4 million in 2022, then rose by 26.59% to $13.1 million in 2023, then jumped by 44.18% to $18.9 million in 2024, then dropped by 10.67% to $16.9 million in 2025, then increased by 28.26% to $21.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $21.7 million (Q1 2026), $16.9 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.